Salud financiera de hoja de balance de Celltrion

Salud financiera controles de criterios 6/6

Celltrion tiene un patrimonio de accionistas total de ₩17,125.8B y una deuda total de ₩1,874.3B, lo que sitúa su ratio deuda-patrimonio en 10.9%. Sus activos y pasivos totales son ₩19,917.5B y ₩2,791.7B respectivamente. El BAIT de Celltrion es de ₩651.4B, por lo que su ratio de cobertura de intereses es de -69.3. Tiene efectivo e inversiones a corto plazo que ascienden a ₩757.5B.

Información clave

10.9%

Ratio deuda-patrimonio

₩1.87t

Deuda

Ratio de cobertura de intereses	-69.3x
Efectivo	₩757.50b
Patrimonio	₩17.13t
Total pasivo	₩2.79t
Activos totales	₩19.92t

Actualizaciones recientes sobre salud financiera

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Mar 19

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Recent updates

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (₩4,880.9B) de A068270 superan a sus pasivos a corto plazo (₩2,470.6B).

Pasivo a largo plazo: Los activos a corto plazo de A068270 (₩4,880.9B) superan a sus pasivos a largo plazo (₩321.2B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (6.5%) de A068270 se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de A068270 ha pasado de 19.9% a 10.9% en los últimos 5 años.

Cobertura de la deuda: La deuda de A068270 está bien cubierta por el flujo de caja operativo (28.7%).

Cobertura de intereses: A068270 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.

Salud financiera de hoja de balance de Celltrion

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Recent updates

Now 21% overvalued after recent price rise

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Consensus EPS estimates fall by 14%

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 16%

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease (IBD)

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩500 per share at 0.3% yield

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,520

Less than half of directors are independent

Now 20% undervalued after recent price drop

Price target decreased to ₩218,897

Full year 2021 earnings: EPS misses analyst expectations

Consensus revenue estimates increase by 10%

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Price target decreased to ₩277,071

Third quarter 2021 earnings released: EPS ₩992 (vs ₩1,251 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ₩919 (vs ₩1,013 in 2Q 2020)

Consensus EPS estimates fall to ₩4,214

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust COVID-19 Ag Rapid Test

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

New 90-day low: ₩300,500

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Celltrion Group Announces Positive Top-Line Efficacy and Safety Data from Global Phase II/III Clinical Trial of COVID-19 Treatment Candidate CT-P59

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Celltrion, Inc. (KOSE:A068270) completed the acquisition of portfolio of select non-core otc and prescription pharmaceutical products exclusively in Asia Pacific from Takeda Pharmaceutical Company Limited (TSE:4502).

Celltrion Completes Enrolment for Global Phase II Clinical Trial with COVID-19 Treatment Candidate CT-P59

New 90-day high: ₩330,000

Celltrion Presents Efficacy and Safety Data for Potential Covid-19 Treatment Candidate Ct-P59 in Patients with Mild Symptoms

New 90-day low: ₩245,500

New 90-day low: ₩278,500

Price target raised to ₩284,353

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera